Cellebrite (CLBT) Q1 2026 earnings review
Solid ARR Growth and Strategic Expansion Unlocks 2026 Momentum
Cellebrite delivered a solid Q1, matching its 'prudent' guidance philosophy with 21% YoY ARR growth and robust 32% TTM Free Cash Flow margins. The strategic pieces for a massive 2026 are falling into place: the US Department of Justice-sponsored FedRAMP High Authorization was achieved, unlocking pent-up federal budgets, and the SCG Canada drone acquisition closed. However, profitability took a sequential step back, with Adjusted EBITDA margins dipping to 23.9% (from near 30% in late 2025). The Q2 guidance signals ARR growth acceleration, but implies continued near-term margin compression before a heavily weighted second half.
🐂 Bull Case
The DOJ officially sponsored Cellebrite Government Cloud for FedRAMP High. This removes a major procurement roadblock and paves the way to tap into previously delayed U.S. Federal spending.
Total ARR grew 21% YoY in Q1, and Q2 guidance projects 22-23% YoY growth. This proves the core demand environment remains highly resilient despite earlier federal lumpiness.
🐻 Bear Case
Adjusted EBITDA margins reversed from nearly 30% in H2 2025 down to 23.9% in Q1. Q2 guidance implies further sequential compression to 22.5% at the midpoint, reflecting acquisition integration costs and FX headwinds.
The recurring revenue dollar-based net retention rate decelerated to 115%, down from 116% in 25Q4 and 121% a year ago, suggesting upsell velocity may be slowing slightly.
⚖️ Verdict: 🟢
Bullish. The top-line momentum (ARR) is accelerating, and the federal spending floodgates are primed to open with FedRAMP High status. The margin dip appears to be a mix of typical H1 seasonality and M&A integration, rather than a structural flaw.
Key Themes
FedRAMP High Catalyst Unlocked
The long-awaited FedRAMP High Authorization was achieved with the U.S. Department of Justice acting as the authorizing agency. This milestone confirms that Cellebrite Government Cloud meets the most stringent federal security requirements. After a choppy 2025 federal spending environment, this authorization serves as the primary mechanism to unlock petabytes of data opportunity across government-wide adoptions.
Cellebrite Genesis AI Enters Beta
Innovation is accelerating with the introduction of 'Cellebrite Genesis,' a purpose-built agentic AI product. It uses conversation-like experiences to analyze mobile extractions, call records, and multimedia. This transforms raw data into actionable insights for complex cases (human trafficking, narcotics). If successfully monetized, this creates an entirely new upsell vector within the existing software stack.
TAM Expansion via Drone Forensics
The acquisition of SCG Canada officially closed on March 1, 2026. This expands Cellebrite's reach into UAVs (drones)—an emerging category seeing robust global growth. SCG provides rapid extraction from over 80 common UAVs at the point of collection, giving law enforcement and defense intelligence a critical new data source.
H1 Profitability Margins Reversing
Despite top-line strength, Adjusted EBITDA margins are decelerating significantly compared to the back half of 2025. After peaking at 29.9% in 25Q3 and 29.8% in 25Q4, margins fell to 23.9% in 26Q1 and are guided down to 22.5% in 26Q2. Management previously cited the absorption of Corellium and FX headwinds, but this places immense execution pressure on the second half of 2026 to hit the 26-27% full-year margin target.
Revenue Growth Trailing ARR Growth
A notable divergence is occurring between forward-looking ARR and recognized revenue. While Q2 ARR guidance implies an accelerating 22.5% YoY growth, total revenue guidance implies decelerating 16% YoY growth. This transition dynamics, typical of SaaS shifts, requires monitoring as the mix heavily tilts away from upfront term licenses.
Corellium Unlocking Automotive Use Cases
Beyond defense and intelligence, Corellium (acquired late 2025) is gaining traction with automotive manufacturers. By virtualizing Arm-based systems at the hardware level, automotive software teams can recreate and test vehicle environments (infotainment, autonomous driving) in the cloud. This provides Cellebrite with a rare enterprise foothold outside of traditional public safety.
Other KPIs
Stable. The TTM FCF margin sits at a highly lucrative 32.0%. Q1 operating cash flow was $19.9M, funding $3.0M in CapEx to yield $16.8M in quarterly free cash flow. This liquidity fully supports the company's aggressive M&A playbook without requiring external financing.
Decelerating. Down from 116% in 25Q4 and 121% in 25Q1. While 115% remains healthy for public sector software, the gradual sequential slide highlights the necessity of new product launches (like Guardian Investigate and Genesis AI) to stimulate deeper cross-selling and upsells within the existing base.
Guidance
Accelerating. The midpoint of $511.5M represents 22.5% YoY growth, an acceleration from Q1's 21%. Management notes that this reflects sequential stability as they gear up to monetize the influx of newly launched products.
Decelerating. The midpoint of $131.5M implies approximately 16% YoY growth, stepping down from the 19% YoY growth delivered in Q1. The lag between ARR growth and revenue growth reflects the ongoing mix shift toward ratable SaaS contracts.
Decelerating. Margins are guided lower sequentially from Q1's 23.9%. This reflects upfront investments in go-to-market for the Spring release cycle and the integration costs of SCG Canada.
Stable. The full-year outlook is maintained, implying 18-19% YoY growth. With Q1 outperforming and Q2 accelerating, this full-year guide currently looks highly conservative.
Reversing. Because H1 2026 margins are hovering in the 22-24% range, achieving the full-year target of 26-27% requires a massive profitability ramp in the second half of the year, echoing typical seasonal patterns where ~60% of EBITDA is generated in H2.
Key Questions
H2 Margin Bridge
With Q1 Adjusted EBITDA margins at 23.9% and Q2 guided to 22.5%, achieving the full-year 26-27% target requires significant H2 leverage. What specific catalysts or expense roll-offs give you confidence in that back-half profitability ramp?
Agentic AI Monetization
Cellebrite Genesis is currently in beta testing. Does the maintained 2026 guidance framework continue to assume zero revenue contribution from these new AI features, and when do you expect them to become a material driver of NRR?
FedRAMP Timeline to ARR
Now that FedRAMP High Authorization is secured, how long is the typical sales cycle to convert this clearance into actual contracted ARR from federal agencies?